Kalvista Pharmaceuticals Inc (KALV)

09:10 AM

KalVista Pharmaceuticals Inc (KALV) stock analysis: A comprehensive overview - uspostnews.com

09:10 AM

03:40 AM

Geode Capital Management LLC Sells 8,632 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

03:40 AM

Apr 23, 2025

Kalvista stock holds $19 target, Market Outperform rating - Investing.com

Apr 23, 2025

Apr 23, 2025

Kalvista stock holds $19 target, Market Outperform rating By Investing.com - Investing.com India

Apr 23, 2025

Apr 22, 2025

Russell Investments Group Ltd. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Apr 22, 2025

Apr 19, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts - Defense World

Apr 19, 2025

Apr 18, 2025

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform - insights.citeline.com

Apr 18, 2025

Apr 17, 2025

(KALV) Trading Report - news.stocktradersdaily.com

Apr 17, 2025

Apr 17, 2025

Vanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Apr 17, 2025

Apr 15, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc. - Defense World

Apr 15, 2025

Apr 15, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc. - Defense World

Apr 15, 2025

Apr 14, 2025

Wellington Management Group LLP Has $1.04 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Apr 14, 2025

Apr 13, 2025

KalVista Pharmaceuticals’ Licensing Agreement with Kaken Pharmaceutical - Global Legal Chronicle

Apr 13, 2025

Apr 13, 2025

The week in pharma: action, reaction and insight – week to April 11 - The Pharma Letter

Apr 13, 2025

Apr 12, 2025

KalVista: Poised For Rare Disease Transformation - Seeking Alpha

Apr 12, 2025

Apr 10, 2025

Kaken, Kalvista partner on HAE treatment sebetralstat in Japan - Angioedema News

Apr 10, 2025

Apr 09, 2025

KalVista licensing deal with Kaken - The Pharma Letter

Apr 09, 2025

Apr 09, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Given “Buy” Rating at Needham & Company LLC - Defense World

Apr 09, 2025

Apr 08, 2025

KalVista inks Japan licensing deal for HAE drug sebetralstat - Investing.com Australia

Apr 08, 2025

Apr 08, 2025

KalVista inks Japan licensing deal for HAE drug sebetralstat By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

KalVista licenses commercialisation rights for HAE to Kaken in Japan - Yahoo

Apr 08, 2025

Apr 08, 2025

Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News

Apr 08, 2025

Apr 08, 2025

KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology

Apr 08, 2025

Apr 08, 2025

KalVista Pharmaceuticals Signs Agreement with Kaken Pharmaceutical - TipRanks

Apr 08, 2025

Apr 08, 2025

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - BioSpace

Apr 08, 2025

Apr 08, 2025

KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan - marketscreener.com

Apr 08, 2025

Apr 08, 2025

KalVista stock rises on licensing deal in Japan (KALV:NASDAQ) - Seeking Alpha

Apr 08, 2025

Apr 08, 2025

Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical To Commercialize Sebetralstat For HAE In Japan - MarketScreener

Apr 08, 2025

Apr 08, 2025

KalVista Pharmaceuticals, Inc. Enters into Licensing Agreement with Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - marketscreener.com

Apr 08, 2025

Apr 05, 2025

Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World

Apr 05, 2025

Apr 04, 2025

Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com

Apr 04, 2025

Apr 03, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace

Apr 03, 2025

Apr 02, 2025

KalVista Strengthens Team with Strategic 87,000-Share Option Grant Package - Stock Titan

Apr 02, 2025

Apr 01, 2025

Where are the Opportunities in (KALV) - news.stocktradersdaily.com

Apr 01, 2025

Mar 31, 2025

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph

Mar 31, 2025

Mar 31, 2025

Charles Schwab Investment Management Inc. Sells 10,372 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Mar 31, 2025

Mar 29, 2025

Q4 Earnings Estimate for KALV Issued By Leerink Partnrs - Defense World

Mar 29, 2025

Mar 28, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from Needham & Company LLC - Defense World

Mar 28, 2025

Mar 27, 2025

KONFIDENT-KID trial of sebetralstat is now fully enrolled - Angioedema News

Mar 27, 2025

Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares By Investing.com - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial - Yahoo Finance

Mar 26, 2025

Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares - Investing.com

Mar 26, 2025

Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target By Investing.com - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 26, 2025

Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target - Investing.com

Mar 26, 2025

Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial - MarketScreener

Mar 25, 2025